Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called RH5.1/Matrix-M. We identify that disordered regions of the full-length...
मुख्य लेखकों: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
Cell Press
2024
|